Navigation Links
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts
Date:3/22/2013

DUBLIN, March 22, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Therapeutic Proteins to 2016. Drugs, Devices, Diseases, Markets and Forecasts" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In recent years, the number of protein-based pharmaceuticals reaching the marketplace has increased exponentially. The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution.

It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration.

These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories. The growth of protein drug products is having a significant effect on the way drugs and devices are developed.

Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.

Highlights:

- Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing and probable future protein drug

- Examines protein delivery design issues, packaging, distribution and technology factors

- Assesses the role of protein formulation decisions on therapeutic protein commercialization and market potential

- Examines historical protein drug data for nine major therapeutic segments and provides forecasts by disease segment to 2016

- Profiles therapeutic protein companies, their commercial products, product development activity, and business strategies

Key Topics Covered:

Executive Summary

Protein Therapeutics Market Dynamics

Therapeutic Protein Commercialization - Success Factors

Protein Drugs - Drug Classes and Therapeutic Targets

Protein Drug Therapeutics - Disease Segment Analysis & Forecasts

Market and Regulatory Factors

Protein Drug Therapeutics - Company Profiles

For more information visit http://www.researchandmarkets.com/research/n4sgxh/therapeutic

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +1-353-1-481-1716


Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DART Therapeutics Develops Drug Candidate for Duchenne Muscular Dystrophy
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
4. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
5. Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
6. Echo Therapeutics Achieves ISO 13485 Certification
7. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
8. Echo Therapeutics Appoints Robert Doman to Board of Directors
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
Breaking Medicine News(10 mins):